Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.39 – $4.10
Volume11,567
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for CMND.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for CMND.
Recent news
Company coverage with links to the original publishers.
Clearmind Medicine announced successful completion of treatment for all 24 participants in Part A of its Phase I/II clinical trial evaluating CMND-100 for alcohol use disorder. The multicenter trial, conducted under FDA oversight at leading U.S. and Israeli research institutions, is progressing to data review with plans to advance to the next phase of development pending favorable results.
Clearmind Medicine Inc. (Nasdaq: CMND) filed a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting PTSD treatment. The filing is part of an exclusive licensing agreement with Yissum Research Development Company of Hebrew University. The global PTSD treatment market is valued at USD 18.5 billion in 2025 and projected to reach USD 30.2 billion by 2035, with Clearmind positioning Hong Kong as a strategic gateway for Asian market access.
Clearmind Medicine received a Nasdaq notice for not meeting minimum bid price requirements, with 180 days to regain compliance or risk potential delisting.
The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.
SciSparc and Clearmind Medicine have filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.